FPS Pharma OEB 7 isolators for the next generation of ultra-potent APIs

Containment as a catalyst for innovation

As pharmaceutical innovation accelerates, the industry stands at a pivotal crossroad.
The emergence of new therapies, particularly in oncology, immunology, and chronic disease management, has ushered in a new generation of ultra-potent APIs with extraordinary biological activity at micrograms or even nanogram dosing level. These compounds hold the promise of transformative clinical outcomes, yet they present unprecedented challenges in manufacturing safety and containment. In this high-stakes environment, FPS Pharma OEB 6 and yet to be formally defined OEB 7 isolators are not merely equipment; they represent a paradigm shift in pharmaceutical containment.

The new arising containment imperative in the ultra-potency era
Handling highly potent APIs (HPAPIs) during early development is fraught with uncertainty. Toxicological data is often incomplete, and establishing a definitive Occupational Exposure Limit (OEL) may be unfeasible at this stage. Yet development and production must continue. To bridge this gap, CDMOs and pharmaceutical manufacturers are adopting risk-based containment strategies that prioritize operator safety without compromising operational efficiency.This is where FPS Pharma concept of OEB 7 comes in. Traditionally, OEB 6 has been considered the upper limit for occupational health banding. Typically, OEB 6 is defined as < 0.1 µg/m³, though it lacks a clearly defined lower threshold. As OEB is a company-defined classification, FPS Pharma has set OEB 6 to span from 0.1 µg/m³ down to 0.01 µg/m³. Given the increasing prevalence of molecules with estimated OELs in the single-digit nanogram range, or even lower, FPS Pharma recognizes the industry’s need for a new tier of containment.

Although the concept of OEB 7 remains unofficial and regulatory harmonization is still pending, this is not merely a numerical extension. It reflects a shift in the design, operation, and validation of future-ready high-containment environments. For these reason FPS Pharma sets OEB 7 at a single-digit nanogram level (< 10 ng/m³).

FPS Pharma’s response: engineering for the unknown
FPS Pharma has positioned itself at the forefront of this technological evolution. Its Class-Division OEB 7 isolators are engineered to meet containment performance targets at the single-digit nanogram level and below, offering a superior level of protection that anticipates the potency of tomorrow’s therapies. These systems are not drawings on paper, FPS Pharma has designed, manufactured, installed them and FPS Pharma customers are operating these isolators today. They are delivering measurable gains in safety and efficiency in real-world HPAPI production.

One notable FPS Pharma case study involves a European pharmaceutical manufacturer facing a significant containment challenge while expanding its facility to process ultra-potent compounds with estimated OELs around 1 ng/m³. The risks were clear: manual powder handling, fragmented workflows, and spatial constraints threatened both safety and productivity. What was required was not just containment, it was equipment integration, precision, and scalability. FPS Pharma delivered a custom OEB 7 isolator that transformed their approach. Compact enough to fit within the existing space, the isolator featured dual glass reactors (25L and 60L) for flexible batch sizes and seamless scale-up. It was equipped with an integrated Agitated Nutsche Filter Dryer (ANFD) for enclosed filtration, drying and final dispensing with closed transfer systems and a cleaning system as well. This tailored solution led to a dramatic reduction in cleaning and validation time. The addition of control systems and a precision dispensing chamber with an integrated weighing scale enabled accurate dosing and packaging without breaching containment. After months of operation, the isolator produced multiple HPAPI batches with optimal quality and safety levels. But the benefits extended beyond containment: cleaning cycles were significantly shortened and downtime was reduced thanks to an ergonomic design that allowed the entire process to be completed within a single isolator, ensuring also operator comfort and ease of movement. Ultimately, this solution translated into faster product delivery and reduced operational costs.

Containment as a catalyst for innovation
What sets FPS Pharma high-containment isolators apart is not only their performance, but their design philosophy. These systems are designed with the understanding that containment is not a constraint, but a catalyst. By enabling the safe handling of ultra-potent APIs, they unlock new possibilities in drug development, allowing manufacturers to explore new types of chemistry and to scale up with confidence. These custom isolators incorporate features such as closed transfer systems (RTPs, SBVs and others), automated cleaning (CIP/WIP), sterilization-in-place (SIP), real-time monitoring, and also advanced features such as robotic and voice-controlled systems. Every element is engineered to minimize contamination risks, maximize precision, optimize operational efficacy, and ensure compliance with the most stringent global standards.

Looking ahead: the role of OEB 7 in future manufacturing
As the pharmaceutical landscape continues to evolve, the demand for higher levels of containment will only intensify. Whether formally adopted in the future as a global standard or used as an internal classification, OEB 7 represents the industry’s commitment to proactive safety, scientific innovation, and operational excellence. In a world where the potency of a compound can no longer be predicted by precedent alone, having the right containment infrastructure is not optional, it is existential. FPS Pharma isolators are more than technical solutions: they are strategic enablers. Then the only question is: what’s next? We will soon share the R&D initiatives that FPS Pharma currently focuses on.